GlassScriptPhysician profile
Robert Davenport-Ray
NPI 1841223799
$681.37
in general payments reported to CMS, 2019-2025
19 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $119 · 2023: $74.46 · 2024: $178 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $81.56 | 2021-2024 | Doc Band |
| Neurelis, INC. | $63.92 | 2023-2025 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $60.40 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.48 | 2021-2022 | |
| Novo Nordisk INC | $47.93 | 2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $45.79 | 2021 | |
| Pfizer INC. | $43.17 | 2024-2025 | |
| Medtronic, INC. | $42.43 | 2023-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Merck Sharp & Dohme LLC | $37.43 | 2021-2024 | Vaxneuvance, Vaxelis, Gardasil |
| Noven Therapeutics, LLC | $24.79 | 2024 | Xelstrym |
| Astellas Pharma US INC | $24.70 | 2024 | Veozah |
| Ironshore Pharmaceuticals INC. | $24.60 | 2023 | Jornay Pm |
| Spr Therapeutics, INC | $23.36 | 2024 | Sprint Pns System |
| Organon LLC | $22.28 | 2022 | |
| Corium, LLC | $20.27 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $20.19 | 2025 | Spinosad, Natroba |
| Biomarin Pharmaceutical INC. | $17.88 | 2025 | Voxzogo 1.2mg |
| Adlon Therapeutics L.P. | $15.61 | 2021 | |
| Glaxosmithkline, LLC. | $13.58 | 2025 | Rotarix, Pediarix, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Davenport-Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.